These data suggest that inhibition of IL-1 signaling by IL-1Ra administration is sufficient to improve obesity-induced hepatic steatosis, in part, by decreasing hepatic lipogenic gene expression and TG accumulation in DIO mouse livers. The gene discussed is IL1A; the disease is obesity due to melanocortin 4 receptor deficiency.